A new mRNA cancer vaccine has shown promising results in reprogramming the immune system to attack tumours within 48 hours. The vaccine has been tested in a human clinical trial with positive outcomes, potentially opening new treatment avenues for aggressive brain tumours.
Key Points
First-ever human clinical trial showed positive results in fighting aggressive brain tumours
mRNA vaccines use similar technology to some Covid vaccines to train the immune system
Results indicate potential for combination approaches with other immunotherapies